Timothy Anderson

Tim Anderson is a managing director at Blue Owl and a member of the healthcare opportunities investment team. In his role, he focuses on investments in biotechnology, diagnostics, and digital medicine companies and sits on the fund’s investment committee. Previously, Tim was a co-founding member and managing director of Cowen Healthcare Investments, the predecessor to Blue Owl. Prior to his role at Cowen Healthcare Investments, Tim was a biotechnology investment banker at Cowen and Company. In addition to serving on the board of Autobahn, he is currently a member of the board of directors of Lycia Therapeutics, F2G, Anaveon, and Scipher Medicine. Tim previously served as a board member or board observer of Tourmaline Bio, Vectiv Bio Holdings, Therachon, Precision Biosciences, Livongo Health, Cadent Therapeutics, Cullinan Oncology and Compass Therapeutics. Tim received a BA in both economics and government & legal studies from Bowdoin College.